Key Points
- Director Thomas Schall bought 21,645 shares of Immuneering on Jan. 15 at an average price of $4.67 for a total of $101,082.15, boosting his stake by 40.93% to 74,530 shares; the transaction was disclosed in an SEC filing.
- IMRX opened at $4.78, has a 1‑year range of $1.10–$10.08, a market cap of about $308.6M and a negative P/E of -2.69, with 50‑ and 200‑day moving averages near $6.28 and $5.83 respectively.
- Institutional investors own roughly 67.65% of the stock, and analysts hold an average rating of "Moderate Buy" with an average price target of $16.50 (several Buy/Outperform ratings and a few higher targets, plus one Sell).
Immuneering Corporation (NASDAQ:IMRX - Get Free Report) Director Thomas Schall bought 21,645 shares of Immuneering stock in a transaction dated Thursday, January 15th. The stock was acquired at an average cost of $4.67 per share, for a total transaction of $101,082.15. Following the completion of the transaction, the director directly owned 74,530 shares in the company, valued at approximately $348,055.10. This trade represents a 40.93% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Immuneering Price Performance
Shares of NASDAQ IMRX opened at $4.78 on Wednesday. Immuneering Corporation has a 1 year low of $1.10 and a 1 year high of $10.08. The firm has a 50-day moving average of $6.28 and a 200 day moving average of $5.83. The stock has a market cap of $308.64 million, a P/E ratio of -2.69 and a beta of 0.48.
Immuneering (NASDAQ:IMRX - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01). Research analysts expect that Immuneering Corporation will post -1.86 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Immuneering
Several institutional investors and hedge funds have recently added to or reduced their stakes in IMRX. Iridian Asset Management LLC CT bought a new position in shares of Immuneering during the 3rd quarter valued at $1,926,000. Flower City Capital bought a new position in Immuneering in the second quarter valued at about $108,000. Kingsview Wealth Management LLC bought a new stake in shares of Immuneering during the 2nd quarter valued at about $47,000. Dimensional Fund Advisors LP increased its position in shares of Immuneering by 46.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company's stock valued at $137,000 after purchasing an additional 6,196 shares during the last quarter. Finally, Corient Private Wealth LLC bought a new position in shares of Immuneering in the 2nd quarter worth approximately $215,000. Hedge funds and other institutional investors own 67.65% of the company's stock.
Wall Street Analyst Weigh In
Several research firms have commented on IMRX. Chardan Capital reissued a "buy" rating and issued a $20.00 target price on shares of Immuneering in a report on Thursday, November 13th. Oppenheimer increased their price objective on shares of Immuneering from $21.00 to $30.00 and gave the company an "outperform" rating in a research report on Thursday, September 25th. Leerink Partners initiated coverage on shares of Immuneering in a research note on Friday, October 31st. They issued an "outperform" rating and a $15.00 target price on the stock. Mizuho set a $12.00 price target on shares of Immuneering in a research report on Wednesday, October 29th. Finally, Wall Street Zen cut Immuneering from a "hold" rating to a "sell" rating in a research report on Saturday, December 20th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $16.50.
Get Our Latest Research Report on Immuneering
About Immuneering
(
Get Free Report)
Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.
The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
